Dermafit Centrum s.r.o.
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases Research
At Dermafit Centrum s.r.o. in Plzen, clinical trials in dermatology focus on common and chronic skin and connective tissue diseases, especially atopic dermatitis and hidradenitis suppurativa. The studies are designed to assess whether new treatments can improve symptoms, maintain control over time, and support better long-term disease management.
- Evaluating new treatment options for atopic dermatitis
- Studying long-term symptom control in hidradenitis suppurativa
- Assessing treatment effectiveness for persistent inflammatory skin conditions
The site’s work in this area reflects a strong interest in improving care for patients with ongoing inflammatory skin disorders, with a focus on both effectiveness and durability of response.
Immune System Diseases Research
This research site also conducts trials in immune system diseases, including chronic spontaneous urticaria, where the goal is to understand how well investigational therapies can reduce symptoms and improve patient quality of life. The studies compare new treatment approaches with placebo or standard care to determine whether they offer better control of immune-driven disease activity.
- Testing therapies for chronic spontaneous urticaria
- Measuring relief of itching, hives, and other disease symptoms
- Comparing new immune-targeted treatments with existing options
These trials highlight the site’s involvement in research aimed at better controlling immune-mediated conditions through more effective and sustained treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novartis Pharma AG2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dermafit Centrum s.r.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Remibrutinib | 4 | Unknown | 2024-03-12 | 2026-06-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.